Chemical formula: C₁₄H₁₁FN₂OS Molecular mass: 273.32 g/mol PubChem compound: 15950376
Flutemetamol ¹⁸F binds to β-amyloid neuritic plaques in the brain. It is a radiopharmaceutical medicinal product indicated for Positron Emission Tomography (PET) imaging of β-amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive impairment. VIZAMYL should be used in conjunction with a clinical evaluation.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| V09AX04 | V Various → V09 Diagnostic radiopharmaceuticals → V09A Central nervous system → V09AX Other central nervous system diagnostic radiopharmaceuticals | |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| VIZAMYL Solution for injection | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
Flutemetamol ¹⁸F is an active ingredient of these brands:
United States (US)Austria (AT)Croatia (HR)Estonia (EE)France (FR)Ireland (IE)Italy (IT)Japan (JP)Lithuania (LT)Poland (PL)Singapore (SG)Spain (ES)Turkey (TR)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
